(Reuters) -Eli Lilly said on Wednesday patients taking ... In the 751-person trial sponsored by Lilly, Zepbound helped patients lose an average of 20.2% of their weight after 72 weeks compared to 13.7% for the group treated with Wegovy, Lilly said.

Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, according to results from a new clinical trial. The study, funded by Lilly, is the first to compare the two drugs directly,

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor